

Please replace the Sequence Listing filed September 27, 2000 located immediately after the abstract with Substitute Sequence Listing enclosed herewith on two (2) CD-Rs in place of the paper copy.

REMARKS

Enclosed herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a Sequence Listing submitted on two (2) identical CD-Rs under 37 C.F.R. §1.821(c) in place of the paper copy. The computer readable form of the Sequence Listing is submitted herewith on one (1) additional CD-R as required by §1.821(e). These three (3) identical CD-R copies of the Sequence Listing, file "0147-0211P.ST25.txt", in no way introduce new matter into the specification.

The substitute Sequence Listing now contains the sequences disclosed in the Specification and Figure 2 that were not made part of the original Sequence Listing. The amendments to the Specification were made to reference these sequences by their SEQ ID NOS. These amendments are editorial in nature and do not constitute new matter.


Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Pursuant to C.F.R. §§1.17 and 1.136(a), the Applicant respectfully petitions for a one (1) month extension of time for filing a response in connection with the present application and the required fee of \$55.00 is attached hereto.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #32,868
for Leonard R. Svensson, #30,330

LRS/KW
0147-0211P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachments: Two (2) CD-Rs as the Paper copy of the Sequence Listing
One (1) CD-R as the Computer Readable form of the Sequence Listing
Copy of Notice to Comply
Version with Markings to Show Changes

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The paragraph beginning on page 10, line 10 has been amended as follows:

It is particularly preferred for the protein encoded by the nucleic acid molecule of the invention to comprise at least one of the following two consensus sequences.

Consensus 1:

EFMLLANXXVAXXIXXXFPXXALLRRHXXP (SEQ ID NO:22)

Consensus 2:

HZALNVXXZTHFTSPIRRZXDVIVHRLAALGY (SEQ ID NO:23)

Moreover, the present invention relates to nucleic acid molecules, the sequence of which deviates from the sequence of one of the above-described nucleic acid molecules because of the degeneracy of the genetic code.

The description of Figure 2 on page 16 has been amended as follows:

Figure 2 shows the first pursued sequencing strategy for sequencing the murine and human LOBO gene (SEQ ID NOS:24-34). As at first only the 3'-end of the gene was sequenced, the exons starting at the 3'-end were numbered 1, 2, 3 etc. Three murine wildtype cosmid clones (middle) were sequenced, two plasmid clones were sequenced from the transgenic LOBO mouse (top) and a human P1-clone (bottom) was sequenced. The arrows denote the exons known for the time being. Seven exons were located on the genomic sequence, the eighth exon at first only existed on an EST clone. The plasmid clones from the transgenic LOBO mouse (top) contain the introduced artificial gene and the adjacent murine sequences. These murine sequences are identical to the corresponding sequences of the wildtype mouse except for 10 base pairs, which have been replaced in the transgenic mouse by the artificial gene.